Lars Egevad

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1691980/publications.pdf

Version: 2024-02-01

328	20,419	13068	13338
papers	citations	68 h-index	130 g-index

337	337	337	20226
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge. Nature Medicine, 2022, 28, 154-163.	15.2	143
2	Ductal and acinar components of mixed prostatic adenocarcinoma frequently have a common clonal origin. Prostate, 2022, 82, 576-583.	1.2	3
3	Percentage grade 4 tumour predicts outcome for prostate adenocarcinoma in needle biopsies from patients with advanced disease: 10-year data from the TROG 03.04 RADAR trial. Pathology, 2022, 54, 49-54.	0.3	7
4	Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3289-3294.	3.3	18
5	Re: Valentin H. Meissner, Isabel Rauscher, Kristina Schwamborn, et al. Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.11.019. European Urology, 2022, , .	0.9	0
6	Detection of perineural invasion in prostate needle biopsies with deep neural networks. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 481, 73-82.	1.4	7
7	External Validation of the Prostate Biopsy Collaborative Group Risk Calculator and the Rotterdam Prostate Cancer Risk Calculator in a Swedish Population-based Screening Cohort. European Urology Open Science, 2022, 41, 1-7.	0.2	4
8	Prognostic significance of percentage Gleason grade 5 prostatic adenocarcinoma in needle biopsies from patients treated by radical prostatectomy. Pathology, 2022, 54, 694-699.	0.3	1
9	Transcriptome-wide prediction of prostate cancer gene expression from histopathology images using co-expression-based convolutional neural networks. Bioinformatics, 2022, 38, 3462-3469.	1.8	9
10	Using deep learning to detect patients at risk for prostate cancer despite benign biopsies. IScience, 2022, 25, 104663.	1.9	5
11	Abstract LB113: Genomic classification to refine prognosis in clear cell renal cell carcinoma. Cancer Research, 2022, 82, LB113-LB113.	0.4	0
12	Histological comparison between predictive value of preoperative 3â€T multiparametric MRI and ⁶⁸Gaâ€PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer. BJU International, 2021, 127, 71-79.	1.3	45
13	Perithyroidal Salivary Gland Acinic Cell Carcinoma: Morphological and Molecular Attributes of a Unique Lesion. Head and Neck Pathology, 2021, 15, 628-637.	1.3	1
14	Artificial intelligence assistance significantly improves Gleason grading of prostate biopsies by pathologists. Modern Pathology, 2021, 34, 660-671.	2.9	84
15	Tumour-like lesions of the urinary bladder. Pathology, 2021, 53, 44-55.	0.3	11
16	Benign mimics of prostate cancer. Pathology, 2021, 53, 26-35.	0.3	7
17	Recent advances in urological pathology. Pathology, 2021, 53, 1-2.	0.3	0
18	Prostatic stromal proliferations: a review. Pathology, 2021, 53, 12-25.	0.3	6

#	Article	IF	Citations
19	Prostate cancer grading, time to go back to the future. BJU International, 2021, 127, 165-168.	1.3	4
20	Histological findings of totally embedded robot assisted laparoscopic radical prostatectomy (RALP) specimens in 1197 men with a negative (low risk) preoperative multiparametric magnetic resonance imaging (mpMRI) prostate lobe and clinical implications. Prostate Cancer and Prostatic Diseases, 2021, 24, 398-405.	2.0	2
21	Staging of renal cell carcinoma: current progress and potential advances. Pathology, 2021, 53, 120-128.	0.3	18
22	Incorporating Magnetic Resonance Imaging and Biomarkers in Active Surveillance Protocols - Results From the Prospective Stockholm3 Active Surveillance Trial (STHLM3AS). Journal of the National Cancer Institute, 2021, 113, 632-640.	3.0	9
23	Intraductal carcinoma of the prostate is not a diagnostic entity. Histopathology, 2021, 78, 342-344.	1.6	6
24	Morphological findings in frozen non-neoplastic kidney tissues of patients with kidney cancer from large-scale multicentric studies on renal cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 1099-1107.	1.4	1
25	Prognostic significance of morphological patterns of Gleason grade 5 prostatic adenocarcinoma diagnosed on needle biopsy. Pathology, 2021, 53, 199-204.	0.3	3
26	The cost-effectiveness of prostate cancer screening using the Stockholm3 test. PLoS ONE, 2021, 16, e0246674.	1.1	11
27	Identifying Prostate Cancer Among Men with Lower Urinary Tract Symptoms. European Urology Open Science, 2021, 24, 11-16.	0.2	2
28	Prognostic role of TSPAN1, KIAA1324 and ESRP1 in prostate cancer. Apmis, 2021, 129, 204-212.	0.9	16
29	Interobserver reproducibility of perineural invasion of prostatic adenocarcinoma in needle biopsies. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 1109-1116.	1.4	7
30	Re: Svetlana Avulova, John C. Cheville, Christine M. Lohse, et al. Grading of Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis. Eur Urol 2021;79:225â€“31. European Urology, 2021, 79, e141-e142.	0.9	2
31	ISUP Consensus Definition of Cribriform Pattern Prostate Cancer. American Journal of Surgical Pathology, 2021, 45, 1118-1126.	2.1	36
32	Temporal changes in causeâ€specific death in men with localised prostate cancer treated with radical prostatectomy: a populationâ€based, nationwide study. Journal of Surgical Oncology, 2021, 124, 867-875.	0.8	1
33	Cribriform prostate cancer: Morphologic criteria enabling a diagnosis, based on survey of experts. Annals of Diagnostic Pathology, 2021, 52, 151733.	0.6	9
34	Intraductal Carcinoma of the Prostate. American Journal of Surgical Pathology, 2021, Publish Ahead of Print, 1527-1533.	2.1	6
35	Artificial Intelligence for Diagnosis and Gleason Grading of Prostate Cancer in Biopsiesâ€"Current Status and Next Steps. European Urology Focus, 2021, 7, 687-691.	1.6	18
36	OpenPhi: an interface to access Philips iSyntax whole slide images for computational pathology. Bioinformatics, 2021, 37, 3995-3997.	1.8	3

#	Article	IF	Citations
37	The emerging role of artificial intelligence in the reporting of prostate pathology. Pathology, 2021, 53, 565-567.	0.3	0
38	Nuclear and stromal expression of Manic fringe in renal cell carcinoma. Experimental and Molecular Pathology, 2021, 122, 104667.	0.9	4
39	The natural history of untreated muscleâ€invasive bladder cancer. BJU International, 2020, 125, 270-275.	1.3	72
40	Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study. Lancet Oncology, The, 2020, 21, 222-232.	5.1	364
41	Perivascular Neuropilinâ€1 expression is an independent marker of improved survival in renal cell carcinoma. Journal of Pathology, 2020, 250, 387-396.	2.1	12
42	Intraductal carcinoma of the prostate is an aggressive form of invasive carcinoma and should be graded. Pathology, 2020, 52, 192-196.	0.3	29
43	Prognostic value of perineural invasion in prostate needle biopsies: a population-based study of patients treated by radical prostatectomy. Journal of Clinical Pathology, 2020, 73, 630-635.	1.0	9
44	The utility of artificial intelligence in the assessment of prostate pathology. Histopathology, 2020, 76, 790-792.	1.6	9
45	Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular Biomarkers in Prostate Cancer. American Journal of Surgical Pathology, 2020, 44, e15-e29.	2.1	40
46	Report From the International Society of Urological Pathology (ISUP) Consultation Conference On Molecular Pathology Of Urogenital Cancers. II. Molecular Pathology of Bladder Cancer. American Journal of Surgical Pathology, 2020, 44, e30-e46.	2.1	38
47	Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. American Journal of Surgical Pathology, 2020, 44, e66-e79.	2.1	26
48	Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. American Journal of Surgical Pathology, 2020, 44, e47-e65.	2.1	68
49	Identification of areas of grading difficulties in prostate cancer and comparison with artificial intelligence assisted grading. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 777-786.	1.4	20
50	Granular necrosis: a distinctive form of cell death in malignant tumours. Pathology, 2020, 52, 507-514.	0.3	20
51	Interleukin-6 derived from cancer-associated fibroblasts attenuates the p53 response to doxorubicin in prostate cancer cells. Cell Death Discovery, 2020, 6, 42.	2.0	55
52	Common benign mimics of prostate cancer. Diagnostic Histopathology, 2020, 26, 305-311.	0.2	3
53	The International Society of Urological Pathology Consultation on Molecular Pathology of Urogenital Cancer. American Journal of Surgical Pathology, 2020, 44, 859-861.	2.1	2
54	Lower urinary tract symptoms (LUTS) are not associated with an increased risk of prostate cancer in men 50â€“69 years with PSA â‰¥3â€‰ng/ml. Scandinavian Journal of Urology, 2020, 54, 1-6.	0.6	11

#	Article	IF	Citations
55	Perineural invasion by prostate adenocarcinoma in needle biopsies predicts bone metastasis: Ten year data from the TROG 03.04 RADAR Trial. Histopathology, 2020, 77, 284-292.	1.6	19
56	Incorporating mpMRI and biomarkers in active surveillance protocols: The prospective Stockholm3 Active Surveillance trial (STHLM3AS).. Journal of Clinical Oncology, 2020, 38, TPS379-TPS379.	0.8	0
57	Assessment of tumourâ€associated necrosis provides prognostic information additional to World Health Organization/International Society of Urological Pathology grading for clear cell renal cell carcinoma. Histopathology, 2019, 74, 284-290.	1.6	24
58	PD â€L1 expression and deficient mismatch repair in ductal adenocarcinoma of the prostate. Apmis, 2019, 127, 554-560.	0.9	11
59	Controversial issues in Gleason and International Society of Urological Pathology (ISUP) prostate cancer grading: proposed recommendations for international implementation. Pathology, 2019, 51, 463-473.	0.3	47
60	Emerging entities of renal cell neoplasia. Surgical and Experimental Pathology, 2019, 2, .	0.2	5
61	Handling and reporting of pelvic lymphadenectomy specimens in prostate and bladder cancer: a webâ€based survey by the European Network of Uropathology. Histopathology, 2019, 74, 844-852.	1.6	7
62	Gene expression profiles define molecular subtypes of prostate cancer bone metastases with different outcomes and morphology traceable back to the primary tumor. Molecular Oncology, 2019, 13, 1763-1777.	2.1	16
63	Are Prostate Specific-Antigen (PSA) and age associated with the risk of ISUP Grade 1 prostate cancer? Results from 72 996 individual biopsy cores in 6 083 men from the Stockholm3 study. PLoS ONE, 2019, 14, e0218280.	1.1	7
64	Dataset for the reporting of prostate carcinoma in radical prostatectomy specimens: updated recommendations from the International Collaboration on Cancer Reporting. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 263-277.	1.4	19
65	Percentage grade 4 tumour predicts outcome for clear cell renal cell carcinoma. Pathology, 2019, 51, 349-352.	0.3	3
66	Intraductal carcinoma of the prostate: a critical re-appraisal. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 525-534.	1.4	40
67	Somatic alterations detected in diagnostic prostate biopsies provide an inadequate representation of multifocal prostate cancer. Prostate, 2019, 79, 920-928.	1.2	9
68	Immunoreactivity for prostate specific antigen and Ki67 differentiates subgroups of prostate cancer related to outcome. Modern Pathology, 2019, 32, 1310-1319.	2.9	37
69	The International Society of Urological Pathology Education webâ€"a web-based system for training and testing of pathologists. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 577-584.	1.4	11
70	Evolution, controversies and the future of prostate cancer grading. Pathology International, 2019, 69, 55-66.	0.6	6
71	PCASTt/SPCG-17â€"a randomised trial of active surveillance in prostate cancer: rationale and design. BMJ Open, 2019, 9, e027860.	0.8	19
72	Is the UICC/AJCC pT2 Staging Category for Clear Cell Renal Cell Carcinoma Meaningful?. American Journal of Surgical Pathology, 2019, 43, 1249-1252.	2.1	8

#	Article	IF	Citations
73	Prostate cancer induces C/EBPÎ² expression in surrounding epithelial cells which relates to tumor aggressiveness and patient outcome. Prostate, 2019, 79, 435-445.	1.2	6
74	Grading of renal cell carcinoma. Histopathology, 2019, 74, 4-17.	1.6	188
75	Dataset for the reporting of prostate carcinoma in core needle biopsy and transurethral resection and enucleation specimens: recommendations from the International Collaboration on Cancer Reporting (ICCR). Pathology, 2019, 51, 11-20.	0.3	19
76	Intraoperative Consultation and Macroscopic Handling. American Journal of Surgical Pathology, 2018, 42, e33-e43.	2.1	16
77	The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential. European Urology, 2018, 74, 204-210.	0.9	68
78	Handling and reporting of transperineal template prostate biopsy in Europe: a web-based survey by the European Network of Uropathology (ENUP). Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 599-604.	1.4	4
79	Utility of Pathology Imagebase for standardisation of prostate cancer grading. Histopathology, 2018, 73, 8-18.	1.6	36
80	Fuhrman grading is inappropriate for papillary renal cell carcinoma. World Journal of Urology, 2018, 36, 1335-1336.	1.2	3
81	Macroscopic features of prostate cancer. Pathology, 2018, 50, 382-388.	0.3	4
82	Balancing Overdiagnosis and Early Detection of Prostate Cancer using the Stockholm-3 Model. European Urology Focus, 2018, 4, 385-387.	1.6	9
83	Oncologic Outcomes After Robot-assisted Radical Prostatectomy: A Large European Single-centre Cohort with Median 10-Year Follow-up. European Urology Focus, 2018, 4, 351-359.	1.6	32
84	The Stockholm-3 (STHLM3) Model can Improve Prostate Cancer Diagnostics in Men Aged 50â€“69 yr Compared with Current Prostate Cancer Testing. European Urology Focus, 2018, 4, 707-710.	1.6	42
85	A novel technique for biobanking of large sections of radical prostatectomy specimens. Histopathology, 2018, 72, 481-489.	1.6	2
86	Contemporary prognostic indicators for prostate cancer incorporating International Society of Urological Pathology recommendations. Pathology, 2018, 50, 60-73.	0.3	29
87	Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis. Genome Medicine, 2018, 10, 85.	3.6	94
88	A minority-group of renal cell cancer patients with high infiltration of CD20+B-cells is associated with poor prognosis. British Journal of Cancer, 2018, 119, 840-846.	2.9	42
89	Re: Comment on Egevad et al., â€˜Utility of Pathology Imagebase for standardisation of prostate cancer gradingâ€™. Histopathology, 2018, 73, 361-362.	1.6	0
90	The current status of renal cell carcinoma and prostate carcinoma grading. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2018, 44, 1057-1062.	0.7	1

#	Article	IF	Citations
91	Accuracy of prostate biopsies for predicting Gleason score in radical prostatectomy specimens: nationwide trends 2000â€“2012. BJU International, 2017, 119, 50-56.	1.3	32
92	Prostate Cancer Grading: A Decade After the 2005 Modified Gleason Grading System. Archives of Pathology and Laboratory Medicine, 2017, 141, 182-183.	1.2	4
93	<scp>UICC</scp> drops the ball in the 8th edition <scp>TNM</scp> staging of urological cancers. Histopathology, 2017, 71, 5-11.	1.6	37
94	Editorial Comment to Biopsy undergrading in men with Gleason score 6 and fatal prostate cancer in the European Randomized study of Screening for Prostate Cancer Rotterdam. International Journal of Urology, 2017, 24, 286-287.	0.5	0
95	Genetic profile of ductal adenocarcinoma of the prostate. Human Pathology, 2017, 69, 1-7.	1.1	20
96	Rhabdoid and Undifferentiated Phenotype in Renal Cell Carcinoma. American Journal of Surgical Pathology, 2017, 41, 253-262.	2.1	56
97	Human cancer-associated fibroblasts enhance glutathione levels and antagonize drug-induced prostate cancer cell death. Cell Death and Disease, 2017, 8, e2848-e2848.	2.7	76
98	Mucinous adenocarcinoma of prostate and prostatic adenocarcinoma with mucinous components: a clinicopathological analysis of 143 cases. Histopathology, 2017, 71, 641-647.	1.6	19
99	Loss of chromosome Y leads to down regulation of KDM5D and KDM6C epigenetic modifiers in clear cell renal cell carcinoma. Scientific Reports, 2017, 7, 44876.	1.6	42
100	Perivascular PDGFR-Î² is an independent marker for prognosis in renal cell carcinoma. British Journal of Cancer, 2017, 116, 195-201.	2.9	33
101	Reply: â€˜A plea for greater standardization in intraductal carcinoma of the prostate â€”greater standardization requires greater evidenceâ€™: let's use the available evidence. Histopathology, 2017, 70, 1013-1014.	1.6	3
102	The decline of medical publishing: the rise of the pseudo-journal. Pathology, 2017, 49, 673-674.	0.3	0
103	Prognostic significance and biopsy characteristics of prostate cancer with seminal vesicle invasion on radical prostatectomy: a nationwide population-based study. Pathology, 2017, 49, 715-720.	0.3	14
104	Clear cell renal cell carcinoma: validation of World Health Organization/International Society of Urological Pathology grading. Histopathology, 2017, 71, 918-925.	1.6	98
105	Pathology Imagebaseâ€”a reference image database for standardization of pathology. Histopathology, 2017, 71, 677-685.	1.6	19
106	The World Health Organization 2016 classification of testicular nonâ€germ cell tumours: a review and update from the International Society of Urological Pathology Testis Consultation Panel. Histopathology, 2017, 70, 513-521.	1.6	143
107	The World Health Organization 2016 classification of testicular germ cell tumours: a review and update from the International Society of Urological Pathology Testis Consultation Panel. Histopathology, 2017, 70, 335-346.	1.6	165
108	Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors. European Urology, 2017, 72, 22-31.	0.9	37

#	Article	IF	Citations
109	Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response. European Urology, 2017, 71, 776-787.	0.9	81
110	Re: Anthony Zietman, Joseph Smith, Eric Klein, Michael Droller, Prokar Dasgupta, James Catto. Describing the Grade of Prostate Cancer: Consistent Use of Contemporary Terminology Is Now Required. Eur Urol 2016;70:1. European Urology, 2017, 71, e52-e53.	0.9	0
111	Reporting intraductal carcinoma of the prostate: a plea for greater standardization. Histopathology, 2017, 70, 504-507.	1.6	22
112	Editorial Comment. Journal of Urology, 2017, 197, 81-82.	0.2	0
113	Characterization of infiltrating lymphocytes in human benign and malignant prostate tissue. Oncotarget, 2017, 8, 60257-60269.	0.8	12
114	One is the new six: The International Society of Urological Pathology (ISUP) patient-focused approach to Gleason grading. Canadian Urological Association Journal, 2016, 10, 339.	0.3	14
115	High Caveolin-1 Expression in Tumor Stroma Is Associated with a Favourable Outcome in Prostate Cancer Patients Managed by Watchful Waiting. PLoS ONE, 2016, 11, e0164016.	1.1	20
116	Pleomorphic giant cell carcinoma of the urinary bladder: an extreme form of tumour deâ€differentiation. Histopathology, 2016, 68, 533-540.	1.6	35
117	International Society of Urological Pathology (<scp>ISUP</scp>) grading of prostate cancer â€“ An <scp>ISUP</scp> consensus on contemporary grading. Apmis, 2016, 124, 433-435.	0.9	152
118	Intraductal carcinoma of prostate reporting practice: a survey of expert European uropathologists. Journal of Clinical Pathology, 2016, 69, 852-857.	1.0	29
119	The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. American Journal of Surgical Pathology, 2016, 40, 244-252.	2.1	2,256
120	In Regard to Zietman et al. International Journal of Radiation Oncology Biology Physics, 2016, 96, 1126-1127.	0.4	3
121	New Gleason grading system: Statement from the editors of 6 journals. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 479-480.	0.8	0
122	Immunohistochemistry of ductal adenocarcinoma of the prostate and adenocarcinomas of nonâ€prostatic origin: a comparative study. Apmis, 2016, 124, 263-270.	0.9	28
123	Prostate cancer grading: recent developments and future directions. BJU International, 2016, 117, 7-8.	1.3	19
124	Gleason and Fuhrman no longer make the grade. Histopathology, 2016, 68, 475-481.	1.6	48
125	Prognostic implications of 2005 Gleason grade modification. Populationâ€based study of biochemical recurrence following radical prostatectomy. Journal of Surgical Oncology, 2016, 114, 664-670.	0.8	8
126	Consensus guidelines for reporting prostate cancer Gleason Grade. BJU International, 2016, 118, E1-2.	1.3	10

#	Article	IF	Citations
127	Reply by the Authors. Urology, 2016, 96, 179-180.	0.5	0
128	Re: Consensus Guidelines for Reporting Prostate Cancer Gleason Grade. Journal of Urology, 2016, 196, 1321-1323.	0.2	0
129	From Gleason to International Society of Urological Pathology (ISUP) grading of prostate cancer. Scandinavian Journal of Urology, 2016, 50, 325-329.	0.6	31
130	Image analysis-derived metrics of histomorphological complexity predicts prognosis and treatment response in stage II-III colon cancer. Scientific Reports, 2016, 6, 36149.	1.6	23
131	Gleason grade 4 prostate adenocarcinoma patterns: an interobserver agreement study among genitourinary pathologists. Histopathology, 2016, 69, 441-449.	1.6	82
132	Ductal adenocarcinoma of the prostate: histogenesis, biology and clinicopathological features. Pathology, 2016, 48, 398-405.	0.3	42
133	Editorial Comment. Journal of Urology, 2016, 195, 1420-1420.	0.2	0
134	International Society of Urological Pathology (ISUP) Grading of Prostate Cancer. American Journal of Surgical Pathology, 2016, 40, 858-861.	2.1	37
135	Reply: Gleason and Fuhrman no longer make the grade. Histopathology, 2016, 69, 341-342.	1.6	0
136	Evaluation of the 2015 Gleason Grade Groups in a Nationwide Population-based Cohort. European Urology, 2016, 69, 1135-1141.	0.9	104
137	The Proteome of Primary Prostate Cancer. European Urology, 2016, 69, 942-952.	0.9	122
138	Largeâ€scale evaluation of SLC18A2 in prostate cancer reveals diagnostic and prognostic biomarker potential at three molecular levels. Molecular Oncology, 2016, 10, 825-837.	2.1	20
139	Utility of Reporting the Percentage of High-grade Prostate Cancer. European Urology, 2016, 69, 599-600.	0.9	14
140	Gene regulatory mechanisms underpinning prostate cancer susceptibility. Nature Genetics, 2016, 48, 387-397.	9.4	119
141	A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. European Urology, 2016, 69, 428-435.	0.9	1,039
142	The prognostic significance of the 2014 International Society of Urological Pathology (ISUP) grading system for prostate cancer. Pathology, 2015, 47, 515-519.	0.3	48
143	Secreted Factors from Colorectal and Prostate Cancer Cells Skew the Immune Response in Opposite Directions. Scientific Reports, 2015, 5, 15651.	1.6	76
144	Confrontation of fibroblasts with cancer cells in vitro: gene network analysis of transcriptome changes and differential capacity to inhibit tumor growth. Journal of Experimental and Clinical Cancer Research, 2015, 34, 62.	3.5	11

#	Article	IF	Citations
145	Diagnosis of Gleason Pattern 5 Prostate Adenocarcinoma on Core Needle Biopsy. American Journal of Surgical Pathology, 2015, 39, 1242-1249.	2.1	43
146	Diagnosis of â€œPoorly Formed Glandsâ€•Gleason Pattern 4 Prostatic Adenocarcinoma on Needle Biopsy. American Journal of Surgical Pathology, 2015, 39, 1331-1339.	2.1	67
147	Upper limit of cancer extent on biopsy defining very lowâ€risk prostate cancer. BJU International, 2015, 116, 213-219.	1.3	20
148	Gleason inflation 1998â€“2011: a registry study of 97â€‰168 men. BJU International, 2015, 115, 248-255.	1.3	68
149	Handling and reporting of orchidectomy specimens with testicular cancer: areas of consensus and variation among 25 experts and 225 European pathologists. Histopathology, 2015, 67, 313-324.	1.6	41
150	Tracking the Origin of Metastatic Prostate Cancer. European Urology, 2015, 67, 819-822.	0.9	79
151	OTUB1 de-ubiquitinating enzyme promotes prostate cancer cell invasion in vitro and tumorigenesis in vivo. Molecular Cancer, 2015, 14, 8.	7.9	52
152	The International Society of Urological Pathology Consensus Conference regarding the classification, prognostic factors, staging, and immunohistochemical and molecular assessment of adult renal tumors. Revista Espanola De Patologia, 2015, 48, 90-96.	0.6	0
153	Active surveillance for prostate cancer: the role of the pathologist. Pathology, 2015, 47, 1-3.	0.3	8
154	Prostate cancer screening in men aged 50â€“69 years (STHLM3): a prospective population-based diagnostic study. Lancet Oncology, The, 2015, 16, 1667-1676.	5.1	308
155	The impact of length and location of positive margins in predicting biochemical recurrence after robot-assisted radical prostatectomy with a minimum follow-up of 5 years. BJU International, 2015, 115, 106-113.	1.3	56
156	High Lysyl Oxidase (LOX) in the Non-Malignant Prostate Epithelium Predicts a Poor Outcome in Prostate Cancer Patient Managed by Watchful Waiting. PLoS ONE, 2015, 10, e0140985.	1.1	16
157	Sorafenib-induced defective autophagy promotes cell death by necroptosis. Oncotarget, 2015, 6, 37066-37082.	0.8	53
158	TMPRSS2-ERG Expression Predicts Prostate Cancer Survival and Associates with Stromal Biomarkers. PLoS ONE, 2014, 9, e86824.	1.1	99
159	Intraductal carcinoma of the prostate: interobserver reproducibility survey of 39 urologic pathologists. Annals of Diagnostic Pathology, 2014, 18, 333-342.	0.6	41
160	The Critical Role of the Pathologist in Determining Eligibility for Active Surveillance as a Management Option in Patients With Prostate Cancer: Consensus Statement With Recommendations Supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists, and the Prostate Cancer Foundation. Archives of Pathology and Laboratory Medicine, 2014, 138, 1387-1405.	1.2	117
161	The reasons behind variation in <scp>G</scp>leason grading of prostatic biopsies: areas of agreement and misconception among 266 <scp>E</scp>uropean pathologists. Histopathology, 2014, 64, 405-411.	1.6	59
162	Diagnostic criteria for ductal adenocarcinoma of the prostate: interobserver variability among 20 expert uropathologists. Histopathology, 2014, 65, 216-227.	1.6	40

#	Article	IF	Citations
163	Optimising pre-analytical factors affecting quality of prostate biopsies: the case for site specific labelling and single core submission. Pathology, 2014, 46, 579-580.	0.3	3
164	Clinical significance of cancer in radical prostatectomy specimens: analysis from a contemporary series of 2900 men. Pathology, 2014, 46, 11-14.	0.3	8
165	Best Practices Recommendations in the Application of Immunohistochemistry in Urologic Pathology. American Journal of Surgical Pathology, 2014, 38, 1017-1022.	2.1	155
166	Best Practices Recommendations in the Application of Immunohistochemistry in the Prostate. American Journal of Surgical Pathology, 2014, 38, e6-e19.	2.1	157
167	A Genetic Score Can Identify Men at High Risk for Prostate Cancer Among Men With Prostate-Specific Antigen of 1â€“3 ng/ml. European Urology, 2014, 65, 1184-1190.	0.9	32
168	Biomarkers in renal cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 464, 359-365.	1.4	27
169	Hypermethylation of the GABREâˆ¼miR-452âˆ¼miR-224 Promoter in Prostate Cancer Predicts Biochemical Recurrence after Radical Prostatectomy. Clinical Cancer Research, 2014, 20, 2169-2181.	3.2	86
170	SOCS2 mediates the cross talk between androgen and growth hormone signaling in prostate cancer. Carcinogenesis, 2014, 35, 24-33.	1.3	42
171	Variation in genomic landscape of clear cell renal cell carcinoma across Europe. Nature Communications, 2014, 5, 5135.	5.8	158
172	Immunohistochemical profile of ductal adenocarcinoma of the prostate. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 559-565.	1.4	26
173	Local and Systemic Protumorigenic Effects of Cancer-Associated Fibroblast-Derived GDF15. Cancer Research, 2014, 74, 3408-3417.	0.4	101
174	Advances in Renal Neoplasia. Urology, 2014, 83, 969-974.	0.5	67
175	High density of S100A9 positive inflammatory cells in prostate cancer stroma is associated with poor outcome. European Journal of Cancer, 2014, 50, 1829-1835.	1.3	37
176	Seminal vesicle intraepithelial involvement by prostate cancer: putative mechanism and clinicopathological significance. Human Pathology, 2014, 45, 1805-1812.	1.1	4
177	Evaluation of Exome Sequencing to Estimate Tumor Burden in Plasma. PLoS ONE, 2014, 9, e104417.	1.1	25
178	ErbB2 Receptor Immunoreactivity in Prostate Cancer: Relationship to the Androgen Receptor, Disease Severity at Diagnosis and Disease Outcome. PLoS ONE, 2014, 9, e105063.	1.1	2
179	PDGFBR expression on perivascular cells influence the prognosis for TKI-treated mRCC pateints in a retrospective cohort study.. Journal of Clinical Oncology, 2014, 32, e15599-e15599.	0.8	0
180	Histopathological features of ductal adenocarcinoma of the prostate in 1,051 radical prostatectomy specimens. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 462, 429-436.	1.4	62

#	Article	IF	Citations
181	The Mitochondrial and Autosomal Mutation Landscapes of Prostate Cancer. European Urology, 2013, 63, 702-708.	0.9	91
182	Exome Sequencing of Prostate Cancer Supports the Hypothesis of Independent Tumour Origins. European Urology, 2013, 63, 347-353.	0.9	134
183	Standardization of Gleason grading among 337 European pathologists. Histopathology, 2013, 62, 247-256.	1.6	148
184	Genetic markers associated with early cancerâ€specific mortality following prostatectomy. Cancer, 2013, 119, 2405-2412.	2.0	81
185	Prognostic significance of patterns of seminal vesicle invasion in prostate cancer. Histopathology, 2013, 62, 1049-1056.	1.6	26
186	Contemporary Grading for Prostate Cancer: Implications for Patient Care. European Urology, 2013, 63, 892-901.	0.9	95
187	Nuclear Stat5a/b predicts early recurrence and prostate cancerâ€“specific death in patients treated by radical prostatectomy. Human Pathology, 2013, 44, 310-319.	1.1	42
188	The International Society of Urological Pathology (ISUP) Grading System for Renal Cell Carcinoma and Other Prognostic Parameters. American Journal of Surgical Pathology, 2013, 37, 1490-1504.	2.1	639
189	The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. American Journal of Surgical Pathology, 2013, 37, 1469-1489.	2.1	922
190	Renal Tumors. American Journal of Surgical Pathology, 2013, 37, 1518-1531.	2.1	154
191	International Society of Urological Pathology (ISUP) Consensus Conference on Renal Neoplasia. American Journal of Surgical Pathology, 2013, 37, 1463-1468.	2.1	41
192	Premalignant lesions of the urinary bladder. Pathology, 2013, 45, 243-250.	0.3	18
193	Handling and Staging of Renal Cell Carcinoma. American Journal of Surgical Pathology, 2013, 37, 1505-1517.	2.1	118
194	Castration Therapy Results in Decreased Ku70 Levels in Prostate Cancer. Clinical Cancer Research, 2013, 19, 1547-1556.	3.2	62
195	Prostate needle biopsy processing: a survey of laboratory practice across Europe. Journal of Clinical Pathology, 2013, 66, 120-123.	1.0	26
196	An interobserver reproducibility study on invasiveness of bladder cancer using virtual microscopy and heatmaps. Histopathology, 2013, 63, 756-766.	1.6	35
197	Prognostic significance of histopathological features of extraprostatic extension of prostate cancer. Histopathology, 2013, 63, 580-589.	1.6	29
198	Association of tumor perivascular desmin expression with survival in patients with sunitinib-treated renal carcinoma.. Journal of Clinical Oncology, 2013, 31, 11097-11097.	0.8	0

#	Article	IF	Citations
199	Implications of the International Society of Urological Pathology Modified Gleason Grading System. Archives of Pathology and Laboratory Medicine, 2012, 136, 426-434.	1.2	58
200	Current routines for transrectal ultrasound-guided prostate biopsy: A web-based survey by the Swedish Urology Network. Scandinavian Journal of Urology and Nephrology, 2012, 46, 405-410.	1.4	9
201	Plasma carotenoids and vitamin C concentrations and risk of urothelial cell carcinoma in the European Prospective Investigation into Cancer and Nutrition. American Journal of Clinical Nutrition, 2012, 96, 902-910.	2.2	43
202	Urological pathology comes of age. Pathology, 2012, 44, 389-390.	0.3	5
203	Biochemical Recurrence After Robot-assisted Radical Prostatectomy in a European Single-centre Cohort with a Minimum Follow-up Time of 5 Years. European Urology, 2012, 62, 768-774.	0.9	85
204	Castration Therapy of Prostate Cancer Results in Downregulation of HIF-1Î± Levels. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1243-1248.	0.4	22
205	Low endoglin vascular density and Ki67 index in Gleason score 6 tumours may identify prostate cancer patients suitable for surveillance. Scandinavian Journal of Urology and Nephrology, 2012, 46, 247-257.	1.4	36
206	Handling and reporting of nephrectomy specimens for adult renal tumours: a survey by the European Network of Uropathology. Journal of Clinical Pathology, 2012, 65, 106-113.	1.0	37
207	Fruit and vegetable consumption and risk of aggressive and non-aggressive urothelial cell carcinomas in the European Prospective Investigation into Cancer and Nutrition. European Journal of Cancer, 2012, 48, 3267-3277.	1.3	26
208	Emphasizing the role of <scp>Wnt5a</scp> protein expression to predict favorable outcome after radical prostatectomy in patients with lowâ€grade prostate cancer. Cancer Medicine, 2012, 1, 96-104.	1.3	20
209	Handling of radical prostatectomy specimens. Histopathology, 2012, 60, 118-124.	1.6	30
210	A Contemporary Update on Pathology Reporting for Prostate Cancer: Biopsy and Radical Prostatectomy Specimens. European Urology, 2012, 62, 20-39.	0.9	85
211	Utility of whole slide imaging and virtual microscopy in prostate pathology. Apmis, 2012, 120, 298-304.	0.9	45
212	Phospho-Akt Immunoreactivity in Prostate Cancer: Relationship to Disease Severity and Outcome, Ki67 and Phosphorylated EGFR Expression. PLoS ONE, 2012, 7, e47994.	1.1	31
213	Identification of New Differentially Methylated Genes That Have Potential Functional Consequences in Prostate Cancer. PLoS ONE, 2012, 7, e48455.	1.1	65
214	Handling and reporting of radical prostatectomy specimens. Diagnostic Histopathology, 2011, 17, 428-433.	0.2	1
215	Diagnostic biomarkers of prostate cancer. Scandinavian Journal of Urology and Nephrology, 2011, 45, 60-67.	1.4	12
216	Prostate Cancer Increases Hyaluronan in Surrounding Nonmalignant Stroma, and This Response Is Associated with Tumor Growth and an Unfavorable Outcome. American Journal of Pathology, 2011, 179, 1961-1968.	1.9	77

#	Article	IF	Citations
217	International Society of Urological Pathology Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Advances in Anatomic Pathology, 2011, 18, 301-305.	2.4	14
218	International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens: rationale and organization. Modern Pathology, 2011, 24, 1-5.	2.9	110
219	Prognostic factors in prostate cancer. Key elements in structured histopathology reporting of radical prostatectomy specimens. Pathology, 2011, 43, 410-419.	0.3	9
220	Handling and reporting of transurethral resection specimens of the bladder in Europe: a webâ€based survey by the European Network of Uropathology (ENUP). Histopathology, 2011, 58, 579-585.	1.6	31
221	Handling of radical prostatectomy specimens: total or partial embedding?. Histopathology, 2011, 59, 1011-1012.	1.6	3
222	Solitary fibrous tumor of the prostate: A report of two cases. Pathology International, 2011, 61, 536-538.	0.6	12
223	Tumour markers in prostate cancer II: Diagnostic and prognostic cellular biomarkers. Acta OncolÃ³gica, 2011, 50, 76-84.	0.8	53
224	Interactive digital slides with heat maps: a novel method to improve the reproducibility of Gleason grading. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 459, 175-182.	1.4	60
225	Fluid intake and the risk of urothelial cell carcinomas in the European Prospective Investigation into Cancer and Nutrition (EPIC). International Journal of Cancer, 2011, 128, 2695-2708.	2.3	58
226	Variety in vegetable and fruit consumption and risk of bladder cancer in the European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, 2011, 128, 2971-2979.	2.3	26
227	LRIG1 and the liar paradox in prostate cancer: A study of the expression and clinical significance of LRIG1 in prostate cancer. International Journal of Cancer, 2011, 128, 2843-2852.	2.3	35
228	Prostate needle biopsy examination by means of virtual microscopy. Pathology Research and Practice, 2011, 207, 366-369.	1.0	17
229	International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 4: seminal vesicles and lymph nodes. Modern Pathology, 2011, 24, 39-47.	2.9	127
230	International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume. Modern Pathology, 2011, 24, 16-25.	2.9	214
231	International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 1: specimen handling. Modern Pathology, 2011, 24, 6-15.	2.9	234
232	International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 5: surgical margins. Modern Pathology, 2011, 24, 48-57.	2.9	239
233	Role of histopathology and molecular markers in the active surveillance of prostate cancer. Acta OncolÃ³gica, 2011, 50, 56-60.	0.8	8
234	Pathology in prostate research: Optimizing the pathological data. Acta OncolÃ³gica, 2011, 50, 49-52.	0.8	7

#	Article	IF	Citations
235	Pathology in prostate research: Optimizing tissue quality. Acta OncolÃ³gica, 2011, 50, 53-55.	0.8	3
236	GAD1 is a biomarker for benign and malignant prostatic tissue. Scandinavian Journal of Urology and Nephrology, 2011, 45, 39-45.	1.4	16
237	Red Meat, Dietary Nitrosamines, and Heme Iron and Risk of Bladder Cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 555-559.	1.1	45
238	Distribution of Foxp3â€, CD4â€•and CD8â€positive lymphocytic cells in benign and malignant prostate tissue. Apmis, 2010, 118, 360-365.	0.9	31
239	Formalin fixation and immunoreactivity in prostate cancer and benign prostatic tissues. Apmis, 2010, 118, 383-388.	0.9	3
240	Genetic profiles in renal tumors. International Journal of Urology, 2010, 17, 6-19.	0.5	10
241	Low Levels of Phosphorylated Epidermal Growth Factor Receptor in Nonmalignant and Malignant Prostate Tissue Predict Favorable Outcome in Prostate Cancer Patients. Clinical Cancer Research, 2010, 16, 1245-1255.	3.2	46
242	Outcome of Primary Versus Deferred Radical Prostatectomy in the National Prostate Cancer Register of Sweden Follow-Up Study. Journal of Urology, 2010, 184, 1322-1327.	0.2	48
243	Mast Cells Are Novel Independent Prognostic Markers in Prostate Cancer and Represent a Target for Therapy. American Journal of Pathology, 2010, 177, 1031-1041.	1.9	189
244	Beta-tubulin III expression in prostate cancer. Scandinavian Journal of Urology and Nephrology, 2010, 44, 371-377.	1.4	16
245	Fatty Acid Amide Hydrolase in Prostate Cancer: Association with Disease Severity and Outcome, CB1 Receptor Expression and Regulation by IL-4. PLoS ONE, 2010, 5, e12275.	1.1	61
246	CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 3414-3419.	3.3	204
247	Donald F. Gleason, 1920â€“2008. European Urology, 2009, 55, 1247-1249.	0.9	3
248	A prospective analysis of the association between dietary fiber intake and prostate cancer risk in EPIC. International Journal of Cancer, 2009, 124, 245-249.	2.3	33
249	Physical activity and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. International Journal of Cancer, 2009, 125, 902-908.	2.3	76
250	Consumption of vegetables and fruit and the risk of bladder cancer in the European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, 2009, 125, 2643-2651.	2.3	42
251	Intra- and interobserver reproducibility of interpretation of immunohistochemical stains of prostate cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2009, 455, 375-381.	1.4	25
252	A high cannabinoid CB1 receptor immunoreactivity is associated with disease severity and outcome in prostate cancer. European Journal of Cancer, 2009, 45, 174-182.	1.3	102

#	Article	IF	Citations
253	Protocol for the Examination of Specimens From Patients With Carcinoma of the Prostate Gland. Archives of Pathology and Laboratory Medicine, 2009, 133, 1568-1576.	1.2	114
254	The European Network of Uropathology: a novel mechanism for communication between pathologists. , 2009, 31, 90-5.		3
255	Endothelin-1 expression in prostate cancer and high grade prostatic intraepithelial neoplasia. , 2009, 31, 137-42.		6
256	Expression of redox pathway enzymes in human prostatic tissue. , 2009, 31, 367-74.		6
257	Expression of PDXâ€1 in prostate cancer, prostatic intraepithelial neoplasia and benign prostatic tissue. Apmis, 2008, 116, 491-498.	0.9	23
258	Heat shock proteins 27, 60 and 70 as prognostic markers of prostate cancer. Apmis, 2008, 116, 888-895.	0.9	69
259	Computerâ€aided ultrasonography (HistoScanning): a novel technology for locating and characterizing prostate cancer. BJU International, 2008, 101, 293-298.	1.3	109
260	Targeted therapies and biological modifiers in urologic tumors: pathobiology and clinical implications. Seminars in Diagnostic Pathology, 2008, 25, 232-244.	1.0	9
261	Atypical stromal hyperplasia of the prostate. Scandinavian Journal of Urology and Nephrology, 2008, 42, 484-487.	1.4	10
262	Alcohol Consumption and the Risk for Prostate Cancer in the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1282-1287.	1.1	37
263	Circulating Concentrations of Folate and Vitamin B12 in Relation to Prostate Cancer Risk: Results from the European Prospective Investigation into Cancer and Nutrition Study. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 279-285.	1.1	49
264	Quantitative Assessment of the Subepithelial Collagen Band Does Not Increase the Accuracy of Diagnosis of Collagenous Colitis. American Journal of Clinical Pathology, 2008, 130, 375-381.	0.4	15
265	Interobserver Variability Between Expert Urologic Pathologists for Extraprostatic Extension and Surgical Margin Status in Radical Prostatectomy Specimens. American Journal of Surgical Pathology, 2008, 32, 1503-1512.	2.1	123
266	Grading of Invasive Cribriform Carcinoma on Prostate Needle Biopsy. American Journal of Surgical Pathology, 2008, 32, 1532-1539.	2.1	85
267	Recent trends in Gleason grading of prostate cancer: I. Pattern interpretation. , 2008, 30, 190-8.		5
268	Primary Seminal Vesicle Carcinoma Detected at Transurethral Resection of Prostate. Urology, 2007, 69, 778.e11-778.e13.	0.5	27
269	Prevalence of prostate cancer at different levels of serum prostate-specific antigen (PSA) and different free:total PSA ratios in a consecutive series of men referred for prostate biopsies. Scandinavian Journal of Urology and Nephrology, 2007, 41, 302-307.	1.4	3
270	Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. American Journal of Clinical Nutrition, 2007, 86, 672-681.	2.2	114

#	Article	IF	Citations
271	Serum androgens and prostate cancer among 643 cases and 643 controls in the European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, 2007, 121, 1331-1338.	2.3	80
272	Proteomics in clinical prostate research. Proteomics - Clinical Applications, 2007, 1, 1058-1065.	0.8	5
273	Editorial Comment on: Immunohistochemical Expression of Endothelin-1 and Endothelin-A and Endothelin-B Receptors in High-Grade Prostatic Intraepithelial Neoplasia and Prostate Cancer. European Urology, 2007, 52, 1689-1690.	0.9	0
274	Tumor specific phage particles promote tumor regression in a mouse melanoma model. Cancer Immunology, Immunotherapy, 2007, 56, 677-687.	2.0	58
275	Prediction of percent Gleason grade 4/5 by multiple core biopsies. Scandinavian Journal of Urology and Nephrology, 2006, 40, 465-471.	1.4	3
276	Proteomic Analysis of Tumor Establishment and Growth in the B16-F10 Mouse Melanoma Model. Journal of Proteome Research, 2006, 5, 1332-1343.	1.8	36
277	Current practice of diagnosis and reporting of prostate cancer on needle biopsy among genitourinary pathologists. Human Pathology, 2006, 37, 292-297.	1.1	49
278	A Working Group Classification of Focal Prostate Atrophy Lesions. American Journal of Surgical Pathology, 2006, 30, 1281-1291.	2.1	123
279	Evaluation of two sample preparation methods for prostate proteome analysis. Proteomics, 2006, 6, 3918-3925.	1.3	12
280	Correlation of protein expression, Gleason score and DNA ploidy in prostate cancer. Proteomics, 2006, 6, 4370-4380.	1.3	33
281	Current practice of diagnosis and reporting of prostatic intraepithelial neoplasia and glandular atypia among genitourinary pathologists. Modern Pathology, 2006, 19, 180-185.	2.9	36
282	Tissue shrinkage after fixation with formalin injection of prostatectomy specimens. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 449, 297-301.	1.4	125
283	The significance of modified Gleason grading of prostatic carcinoma in biopsy and radical prostatectomy specimens. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 449, 622-627.	1.4	145
284	Cytological features of prostatic intraepithelial neoplasia. Diagnostic Cytopathology, 2006, 34, 317-322.	0.5	9
285	Switch to full-length of XAF1 mRNA expression in prostate cancer cells by the DNA methylation inhibitor. International Journal of Cancer, 2006, 118, 2485-2489.	2.3	35
286	CD4+CD25high T Cells Are Enriched in the Tumor and Peripheral Blood of Prostate Cancer Patients. Journal of Immunology, 2006, 177, 7398-7405.	0.4	373
287	Ezrin Expression in Prostate Cancer and Benign Prostatic Tissue. European Urology, 2005, 48, 852-857.	0.9	34
288	Tumor Size, Vascular Density and Proliferation as Prognostic Markers in GS 6 and GS 7 Prostate Tumors in Patients with Long Follow-Up and Non-Curative Treatment. European Urology, 2005, 48, 577-583.	0.9	33

#	Article	IF	Citations
289	Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine. Prostate, 2005, 62, 217-223.	1.2	47
290	Angiopoietin 2 expression is related to histological grade, vascular density, metastases, and outcome in prostate cancer. Prostate, 2005, 62, 394-399.	1.2	71
291	Presence and specificity of tumor associated lymphocytes from ascites fluid in prostate cancer. Prostate, 2005, 65, 20-26.	1.2	6
292	Differential protein expression in anatomical zones of the prostate. Proteomics, 2005, 5, 2570-2576.	1.3	31
293	Prediction of the volume of large prostate cancers by multiple core biopsies. Scandinavian Journal of Urology and Nephrology, 2005, 39, 380-386.	1.4	4
294	The significance of tumor heterogeneity for prediction of DNA ploidy of prostate cancer. Scandinavian Journal of Urology and Nephrology, 2005, 39, 387-392.	1.4	16
295	Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens. Scandinavian Journal of Urology and Nephrology, 2005, 39, 20-33.	1.4	114
296	Prognostic and predictive factors in prostate cancer: Historical perspectives and recent international consensus initiatives. Scandinavian Journal of Urology and Nephrology, 2005, 39, 8-19.	1.4	41
297	Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scandinavian Journal of Urology and Nephrology, 2005, 39, 34-63.	1.4	194
298	Current practice of Gleason grading among genitourinary pathologists. Human Pathology, 2005, 36, 5-9.	1.1	52
299	Pim-1 expression in prostatic intraepithelial neoplasia and human prostate cancer. Prostate, 2004, 60, 367-371.	1.2	115
300	Fruits and vegetables and prostate cancer: No association among 1,104 cases in a prospective study of 130,544 men in the European Prospective Investigation into Cancer and Nutrition (EPIC). International Journal of Cancer, 2004, 109, 119-124.	2.3	100
301	Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 811-816.	3.3	1,175
302	Interobserver Reproducibility of Percent Gleason Grade 4/5 in Prostate Biopsies. Journal of Urology, 2004, 171, 664-667.	0.2	36
303	Expression of ezrin in prostatic intraepithelial neoplasia. Urology, 2004, 63, 609-612.	0.5	46
304	Overexpression of IGBFB2 is a marker for malignant transformation in prostate epithelium. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2003, 442, 329-335.	1.4	34
305	Interobserver reproducibility of modified Gleason score in radical prostatectomy specimens. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2003, -1, 1-1.	1.4	26
306	Cytology of the central zone of the prostate. Diagnostic Cytopathology, 2003, 28, 239-244.	0.5	8

#	Article	IF	Citations
307	Molecular epidemiology of VHL gene mutations in renal cell carcinoma patients: relation to dietary and other factors. Carcinogenesis, 2002, 23, 809-815.	1.3	24
308	Interobserver Reproducibility of Percent Gleason Grade 4/5 in Total Prostatectomy Specimens.. Journal of Urology, 2002, 168, 2006-2010.	0.2	27
309	Percent Gleason Grade 4/5 as Prognostic Factor in Prostate Cancer Diagnosed at Transurethral Resection. Journal of Urology, 2002, 168, 509-513.	0.2	57
310	Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate, 2002, 51, 268-275.	1.2	156
311	Ultrastructure of the secretion of prostasomes from benign and malignant epithelial cells in the prostate. Prostate, 2002, 53, 192-199.	1.2	64
312	Percent Gleason Grade 4/5 as Prognostic Factor in Prostate Cancer Diagnosed at Transurethral Resection. Journal of Urology, 2002, , 509-513.	0.2	2
313	Interobserver Reproducibility of Percent Gleason Grade 4/5 in Total Prostatectomy Specimens.. Journal of Urology, 2002, , 2006-2010.	0.2	1
314	Percent Gleason grade 4/5 as prognostic factor in prostate cancer diagnosed at transurethral resection. Journal of Urology, 2002, 168, 509-13.	0.2	11
315	Interobserver reproducibility of percent Gleason grade 4/5 in total prostatectomy specimens. Journal of Urology, 2002, 168, 2006-10.	0.2	12
316	Reproducibility of Gleason grading of prostate cancer can be improved by the use of reference images. Urology, 2001, 57, 291-295.	0.5	63
317	Automatic Registration and Error Detection of Multiple Slices Using Landmarks. Analytical Cellular Pathology, 2001, 23, 159-165.	2.1	0
318	VHL gene alterations in renal cell carcinoma patients: novel hotspot or founder mutations and linkage disequilibrium. Oncogene, 2001, 20, 5393-5400.	2.6	47
319	Messenger Ribonucleic Acid Levels of Steroid 5Î±-Reductase 2 in Human Prostate Predict the Enzyme Activity¹. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 855-858.	1.8	27
320	Polypeptide Expression in Prostate Hyperplasia and Prostate Adenocarcinoma. Analytical Cellular Pathology, 2000, 21, 1-9.	2.1	80
321	Plasma Insulin-Like Growth Factor-I, Insulin-Like Growth Factor-Binding Proteins, and Prostate Cancer Risk: a Prospective Study. Journal of the National Cancer Institute, 2000, 92, 1910-1917.	3.0	336
322	Distribution of prostasomes in neoplastic epithelial prostate cells. , 1999, 39, 36-40.		21
323	Estimation of prostate cancer volume by multiple core biopsies before radical prostatectomy. Urology, 1998, 52, 653-658.	0.5	36
324	A New Method for Handling Radical Prostatectomies Enabling Fresh Tissue Harvesting, Whole Mount Sections, and Landmarks for Alignment of Sections. Journal of Urologic Pathology, 1998, 9, 17-28.	0.3	24

#	Article	IF	Citations
325	A New Method for Segmentation of Colour Images Applied to Immunohistochemically Stained Cell Nuclei. Analytical Cellular Pathology, 1997, 15, 145-156.	2.1	52
326	Transrectal Ultrasonically-Guided Core Biopsies In The Assessment Of Local Cure Of Prostatic Cancer After Radical External Beam Radiotherapy. Acta OncolÃ³gica, 1995, 34, 945-952.	0.8	22
327	Oncological and urinary outcomes following <scp>LDR</scp> Brachytherapy with median follow up of 11.8â€‰years. BJU International, 0, , .	1.3	0
328	Intraductal Carcinoma of the Prostate and Nuclear Size. American Journal of Surgical Pathology, 0, Publish Ahead of Print, .	2.1	0